Navigation Links
Generex Provides Update on Bloomberg TV Breast Cancer Vaccine Segment

WORCESTER, Mass. and TORONTO, Dec. 20, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that the Bloomberg Television segment on the Antigen Express breast cancer vaccine did not air yesterday as originally scheduled (and announced in Bloomberg Television's December 16, 2011 promotional spot).  The Company will provide a further update once representatives of Bloomberg Television advise as to a rescheduled air date and time.


About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at or the Antigen Express website at

Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015  Strengthening its leadership in ... AEX: PHIA) today announced IntelliSpace Portal 8.0 , ... and visualization platform that helps radiologists detect, diagnose and ... 2015 Radiological Society of North America Annual Meeting (RSNA) ... Portal 8.0 helps address the changing demands in radiology ...
(Date:11/29/2015)... 29, 2015   Royal Philips  (NYSE: PHG, AEX: ... at the 2015 Radiological Society of North America Annual ... Place in Chicago . Visitors to ... company,s broad portfolio of integrated Diagnostic Imaging, Clinical Informatics, ... clinical performance, improve workflow and create a superior patient ...
(Date:11/29/2015)... Germany , Nov. 29, 2015  At ... invites attendees to experience the most complete mobile C-arm ... on display is Ziehm Vision RFD 3D, the world,s ... 16 cm edge length per scan volume. In addition, ... first fully motorized mobile C-arm in four axes which ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... ... the American Institute of Ultrasound in Medicine! , AIUM ultrasound practice accreditation ... they meet or exceed nationally recognized standards in the performance and interpretation ...
(Date:11/29/2015)... (PRWEB) , ... November 29, 2015 , ... "I struggled ... Things that as a Mother and Wife would love to do, I missed. We ... I just happened to call Dr. Zaidan first. They have changed my life drastically. ...
(Date:11/29/2015)... ... ... Cyber Monday deal is a deep 40% or more discount on every item on both ... skin care lover in your circle. Each Christmas, Sublime Beauty offers a special ... are staples: Collagen, Retinol and Hyaluronic Serums. , Stocking stuffers like Skin Brushes, natural Body ...
(Date:11/29/2015)... (PRWEB) , ... November 29, 2015 , ... NewsWatch featured ... technology products available to consumers. Amanda Forstrom, a technology expert and special reporter for ... be a reality in the future. , It’s the future because flying cars are ...
(Date:11/29/2015)... Ca (PRWEB) , ... November 29, 2015 , ... Khanna ... American Board of Ophthalmology on November 25th 2015. Peer Certification by the ... field of his specialty. Certification in Ophthalmology is first obtained after the completion of ...
Breaking Medicine News(10 mins):